Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by BTG International Inc.
Biocompatibles UK Ltd
Information provided by (Responsible Party):
BTG International Inc.
ClinicalTrials.gov Identifier:
First received: November 24, 2011
Last updated: May 25, 2016
Last verified: May 2016
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.

Condition Intervention Phase
Colorectal Cancer Metastatic
Device: TheraSphere
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy

Resource links provided by NLM:

Further study details as provided by BTG International Inc.:

Primary Outcome Measures:
  • Progression free survival [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 340
Study Start Date: January 2012
Estimated Study Completion Date: February 2019
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment group
Standard of care second-line chemotherapy plus TheraSphere
Device: TheraSphere
yttrium 90 microspheres
No Intervention: Control group
Standard of care second-line chemotherapy with no added therapy


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Must be male or female, 18 years of age or older, and of any ethnic or racial group
  • Unresectable primary tumor must be stable or asymptomatic
  • Colorectal cancer with unresectable metastatic disease to the liver (unresectable unilobar or bilobar disease) who have disease progression with oxaliplatin or irinotecan based first line chemotherapy
  • Eligible to receive second-line standard-of-care chemotherapy with either 1) an oxaliplatin-based chemotherapy regimen, or 2) an irinotecan-based chemotherapy regimen
  • Baseline efficacy images with measurable target tumors in the liver according to RECIST 1.1 using standard imaging techniques taken within 28 days prior to randomization. Images must be taken after, or at the time of completion of first line chemotherapy
  • Tumor replacement <50% of total liver volume
  • ECOG of 0-1 through screening to first treatment
  • First line chemotherapy regimen completed at least 14 days prior to initiation of 2nd line chemotherapy under the protocol
  • Patient is willing to participate in the study and has signed the study informed consent
  • Serum creatinine ≤ 2.0 mg/dL
  • Serum bilirubin 1.2 x upper limit of normal
  • Albumin ≥ 2.0 g/dL
  • Neutrophil count >1200/cubic mm

Exclusion Criteria

  • History of hepatic encephalopathy
  • Contraindications to angiography and selective visceral catheterization such as bleeding diathesis or coagulopathy that is not correctable by usual therapy of hemostatic agents
  • History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
  • Presentation of pulmonary insufficiency or clinically evident chronic obstructive pulmonary disease
  • Cirrhosis or portal hypertension
  • Prior external beam radiation treatment to the liver
  • Prior intra-arterial liver directed therapy, including TACE or Y-90 microsphere therapy
  • Planned treatment with VEGF inhibitors within 28 days prior to receiving TheraSphere (may resume after Y-90 treatment or immediately if in control arm)
  • Planned liver directed therapy or radiation therapy
  • Intervention for, or compromise of, the Ampulla of Vater
  • Clinically evident ascites (trace ascites on imaging is acceptable)
  • Toxicities due to prior cancer therapy that have not resolved before the initiation of study treatment, if the Investigator determines that the continuing complication will compromise the safe treatment of the patient
  • Significant life-threatening extra-hepatic disease, including patients who are on dialysis, have unresolved diarrhea, have serious unresolved infections including patients who are known to be HIV positive or have acute HBV or HCV
  • Significant extra-hepatic metastases. Limited extra-hepatic metastases in the lung and/or lymph nodes are permitted (up to 5 lesions in the lung, with each individual lesion <1 cm; any number of lymph lesions with each individual lesion <1.5 cm)
  • Contraindications to the planned second line standard-of-care chemotherapy regimen
  • Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization, and must not be breastfeeding
  • Participation in a clinical trial with an investigational therapy within 30 days prior to randomization
  • Co-morbid disease or condition that would place the patient at undue risk and preclude safe use of TheraSphere treatment, in the Investigator's judgment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01483027

Contact: Helen Stiffler, MSN,RN (919) 471 7376 Helen.Stiffler@TheoremClinical.com
Contact: Carrie Hansen +760-473-1032 carrie.hansen@Chiltern.cpm

  Hide Study Locations
United States, California
UCSF Helen Diller Family Comprehensive Cancer Center Recruiting
San Francisco, California, United States, 94115
Contact: Curt Johanson    415-353-2310    curt.johanson@cc.ucsf.edu   
Principal Investigator: Nicholas Fidelman, MD         
United States, District of Columbia
George Washington University Hospital Withdrawn
Washington, District of Columbia, United States, 20037
United States, Illinois
Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Asley Roche    312-563-2169    ashley_roche@rush.edu   
Principal Investigator: Marisa Hill, MD         
Northwestern Memorial Hospital Recruiting
Chicago, Illinois, United States, 60611
Contact: Carlene del Castillo    312-695-1518    carlene.castillo@northwestern.edu   
Principal Investigator: Mary Mulcahy, MD         
United States, Indiana
Indiana University School of Medicine Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Tamiko MaGee    317-278-7557    trmagee@iupui.edu   
Principal Investigator: Matthew S Johnson, MD         
United States, Kentucky
University of Louisville Recruiting
Louisville, Kentucky, United States, 40202
Contact: Melissa Schlegel    502-629-3383    melissa.schlegel@louisville.edu   
Principal Investigator: Robert Martin, MD, PhD         
United States, Maryland
The Johns Hopkins Hospital Withdrawn
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Lahey Clinic - Tufts University Recruiting
Burlington, Massachusetts, United States, 01805
Contact: Nanette Matrullo, MD    781-744-4290    nanette.matrullo@lahey.org   
Principal Investigator: Shams Iqbal, MD         
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Debra Krease    734-764-6847    debraakr@med.umich.edu   
Principal Investigator: Mary Feng, MD         
Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Colette Zack    313-576-9385    zackc@karmanos.org   
Principal Investigator: Phillip Phillip, MD         
Saint Mary's Healthcare Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Kathy Estkowski    616-685-5156    estkowk@mercyhealth.com   
Principal Investigator: Matthew A Tiede, MD         
Spectrum Health / Advanced Radiology Services Recruiting
Grand Rapids, Michigan, United States, 49506
Contact: Kimberly Mohr, BSN,RN,CCRC    616-486-6111    kimberly.mohr@spectrumhealth.org   
Principal Investigator: Manish Varma, MD         
United States, Minnesota
Virginia Piper Cancer Institute, Abbott Northwestern Hospital Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Lisa Albers    612-863-9466    lisa.albers@allina.com   
Principal Investigator: Joseph Leach, MD         
Mayo Clinic Withdrawn
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University Recruiting
St Louis, Missouri, United States, 63110
Contact: Robin Haverman    314-747-1624    havermanr@wustl.edu   
Principal Investigator: Darryl Zuckerman, MD         
United States, New York
University of Rochester, James P Wilmot Cancer Ctr Recruiting
Rochester, New York, United States, 14642
Contact: Laurie Koek    585-275-8213    Laurie_koek@urmc.rochester.edu   
Principal Investigator: Marcus Noel, MD         
United States, Ohio
Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Saba Elias       saba.elias@osumc.edu   
Principal Investigator: Hooman Khabiri, MD         
Miami Valley Hospital Recruiting
Dayton, Ohio, United States, 45409
Contact: Kimberly Garrett    937-208-3307    kjgarrett@PremierHealth.com   
Principal Investigator: Shannon Kauffman, MD         
United States, Pennsylvania
Hospital of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Evelyn Stainthorpe, BS, CCRC    212-662-6983    evelyn.stainthorpe@uphs.upenn.edu   
Principal Investigator: Michael C Soulen, MD         
Diagnostic Imaging Inc Recruiting
Trevose, Pennsylvania, United States, 19053
Contact: Sally Wagenborg, RN, CCRP    215-612-4881    swagenborg@ariahealth.org   
Principal Investigator: Aaron Shiloh, MD         
United States, Texas
UT Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Christina Carrigan    214-645-2704    christina.carrigan@utsouthwestern.edu   
Principal Investigator: Anil Pillai, MD         
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Cynthia Brown    713-792-2924    cbrown@mdanderson.org   
Principal Investigator: Armeen Mahvash, MD         
United States, Utah
St. Marks Hospital Recruiting
Salt Lake City, Utah, United States, 84124
Contact: Melinda Turpin    801-831-0512    melinda.turpin@mountainstarhealth.com   
Principal Investigator: James Carlisle, MD         
United States, Virginia
University of Virginia Health System Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Royanne Koogler    434-924-9496    RLB8Y@virginia.edu   
Contact: Snjezana Zaja-Milatovic    434-243-6575    SZ7S@virginia.edu   
Principal Investigator: James Stone, MD         
Sentara Cancer Research Recruiting
Norfolk, Virginia, United States, 23507
Contact: Angela Bowman    757-388-1926    ambowman@sentara.com   
Principal Investigator: Harlan Vingan, MD         
United States, Washington
University of Washington Recruiting
Seattle, Washington, United States, 98195
Contact: Stephanie DiGiacomo    206-288-6358    sdigiaco@seattlecca.org   
Principal Investigator: Siddharth Padia, MD         
Principal Investigator: William P Harris, MD         
United States, Wisconsin
University of Wisconsin Hospital & Clinics Withdrawn
Madison, Wisconsin, United States, 53792
Medical College of Wisconsin, Inc. Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Elizabeth Weil    414-805-3028    eweil@mcw.edu   
Principal Investigator: William Rilling, MD         
AZ - Sint Lucas Ziekemhuis Recruiting
Gent, Oost-Vlaander, Belgium, 9000
Contact: Joline Goossens    0032 9 224 6227    Joline.Goossens@AZSTLUCAS.BE   
Principal Investigator: Johan Van Ongeval, MD         
Canada, Nova Scotia
QEII Health Services Center Recruiting
Halifax, Nova Scotia, Canada, B3H 3A7
Contact: Lorrie Yunace    902-473-6105    lorrie.yunace@nshealth.ca   
Principal Investigator: Robert Abraham, MD         
Canada, Ontario
London Regional Cancer Centre Recruiting
London, Ontario, Canada, N6A 4L6
Contact: Anne Malpage    519-685-8618    anne.malpage@lhsc.on.ca   
Principal Investigator: Stephen Welch, MD         
Mount Sinai Hospital Recruiting
Toronto, Ontario, Canada, M5G 1X5
Contact: Cheryl Geen-Smith    (416) 946-4501 ext 6639    cheryl.geen-smith@uhn.ca   
Principal Investigator: John Beecroft, MD         
Canada, Quebec
McGill University Health Centre / Royal Victoria Hospital Recruiting
Montreal, Quebec, Canada, H3A 1A1
Contact: Ayat Salman    (514) 934-1934 ext 36237    Ayat.Salman@MUHC.MCGILL.CA   
Principal Investigator: Tatiana Cabrera, MD         
Hong Kong Sanatorium and Hospital Recruiting
Hong Kong, China
Contact: Janet Leung    852-2835-8877    janet.ky.leung@hksh.com   
Principal Investigator: Thomas Leung, MD         
Queen Mary Hospital Recruiting
Hong Kong, China
Contact: Carolyn Heung    852-2255-4216    heungkl@hku.hk   
Principal Investigator: Victor Lee, MD         
Czech Republic
Clinici of Imaging Methods - University Hospital Plzen Withdrawn
Plzen, Czech Republic, 30640
Centre Eugene Marquis Recruiting
Rennes, France, 35042
Contact: Gaelle Kergoat    33 299 25 32 61    g.kergoat@rennes.unicancer.fr   
Principal Investigator: Marc Pracht, MD         
Universitaria di Bologna Recruiting
Bologna, Italy, 40138
Principal Investigator: Rita Golfieri, MD         
National University Hospital Singapore Recruiting
Singapore, Singapore, 119228
Contact: Patrick Marban       csimpc@nus.edu.sg   
Principal Investigator: Thomas Soh, MD         
Hospital Universitario Puerta de Hierro Recruiting
Majadahonda, Madrid, Spain, 28220
Contact: Rocio Navarro    0034 911 917 418    rocio.navarro@salud.madrid.org   
Principal Investigator: Ana Ruiz Casado, MD         
Hospital Universitario Ramon y Cajal Recruiting
Madrid, Spain, 28034
Contact: Cristina Carrera       cristina.carrera.hryc@gmail.com   
Principal Investigator: Carmen Guillen Ponce, MD         
University Hospital "Fundacion Jimenez Diaz" Recruiting
Madrid, Spain, 28040
Contact: Margarita Lobo    34 915 504 800 ext 2299    mlobo@fjd.es   
Principal Investigator: Ana Leon, MD         
United Kingdom
Churchill Hospital Recruiting
Oxford, England, United Kingdom, OX3 7LE
Contact: Anju Chalin    0044 1865 235309    trialadministrator07@oncology.ox.ac.uk   
Principal Investigator: Ricky Sharma         
Edinburgh Cancer Centre - Western General Hospital Recruiting
Edinburgh, United Kingdom, EH4 2XU
Contact: Moira Stewart    0131 537 2201    moira.stewart11@ed.ac.uk   
Principal Investigator: Ewan Brown, MD         
Royal Surrey County Hospital Recruiting
Guildford, United Kingdom, GU2 7XX
Contact: Ceri Jamieson    0148 340 66 12    cerijamieson@nhs.net   
Principal Investigator: Tony Dhillon, MD         
Guy's Hospital Recruiting
London, United Kingdom, SE1 9RT
Contact: Lorna Caplis    020 7188 8718    loma.caplis@gstt.nhs.uk   
Principal Investigator: Paul Ross, MD         
Nottingham University Hospital NHS Trust Recruiting
Nottingham, United Kingdom, NG5 1PB
Contact: Jackie Worville    0115 969 1169 ext 54692    jackie.worville@nuh.nhs.uk   
Principal Investigator: Jamie Mills, MD         
Western Park Hospital - Sheffield Teaching Hospitals Trial Center Recruiting
Sheffield, United Kingdom, NW3 2QG
Contact: Alison Redfearn    0044 114 226 51 60    a.redfearn@sheffield.ac.uk   
Principal Investigator: Joanne Hornbuckle, MD         
Sponsors and Collaborators
BTG International Inc.
Biocompatibles UK Ltd
Principal Investigator: Mary Mulcahy, MD Northwestern University
Principal Investigator: Ricky Sharma, MA FRCP FRCR PhD University of Oxford
  More Information

Responsible Party: BTG International Inc.
ClinicalTrials.gov Identifier: NCT01483027     History of Changes
Other Study ID Numbers: TS-102 
Study First Received: November 24, 2011
Last Updated: May 25, 2016
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases

ClinicalTrials.gov processed this record on May 26, 2016